Stay updated with breaking news from Chronic Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least
Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96...
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-week
This 3D bioprinting technology, developed by Tel Aviv University was tested on mice with both acute and chronic paralysis. The results from the tests showed that all mice with acute paralysis regained the ability to walk. The success rate in mice with chronic paralysis was 80%.